M2 mutations of the nicotinic acetylcholine receptor increase the potency of the non-competitive inhibitor phencyclidine. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

M2 mutations of the nicotinic acetylcholine receptor increase the potency of the non-competitive inhibitor phencyclidine.

Eaton MJ, Labarca C, Eterov?c VA. M2 mutations of the nicotinic acetylcholine receptor increase the potency of the non-competitive inhibitor phencyclidine. J Neurosci Res. 2000 Jul 01; 61(1):44-51.

View in: PubMed

authors with profiles

Vesna A. Eterovic

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support